Form 4: Enliven Therapeutics CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Enliven Therapeutics' President and CEO, Samuel Kintz, sold 12,500 shares of common stock for approximately $21.33 per share under a pre-arranged trading plan.
Summary
- Samuel Kintz, President and CEO of Enliven Therapeutics, Inc. (ELVN), reported the sale of 12,500 shares of common stock.
- The transaction occurred on October 17, 2025, at a weighted average price of $21.3323 per share.
- The total value of the shares sold was approximately $266,653.75.
- This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Kintz on November 15, 2024.
- Following this transaction, Mr. Kintz beneficially owns 902,892 shares, held indirectly through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a pre-planned sale under a Rule 10b5-1 trading plan, which is a routine event for executives and does not typically reflect a change in management's outlook on the company's performance.
Industry Context
This filing reports a routine insider transaction for Enliven Therapeutics, Inc., which is common across all industries for executives managing their personal stock holdings, particularly through pre-arranged 10b5-1 plans.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in direct insider ownership, but the pre-planned nature mitigates concerns about management's confidence.
Key Dates
| Date | Description |
|---|---|
| 11/15/2024 | Rule 10b5-1 trading plan adopted by Samuel Kintz. |
| 10/17/2025 | Transaction date for the sale of 12,500 common shares. |
| 10/21/2025 | Date the Form 4 was signed by power of attorney. |
Recommendation
holdThe sale of shares by President and CEO Samuel Kintz was conducted under a pre-arranged Rule 10b5-1 trading plan, adopted nearly a year prior to the transaction date. Such planned sales are generally considered routine and do not typically signal a change in management's outlook on the company's prospects. Therefore, this specific insider transaction alone does not provide a strong basis for altering an existing investment thesis, leading to a 'hold' recommendation.
Keywords
ELVN, Enliven Therapeutics, Samuel Kintz, Insider Trading, Stock Sale, 10b5-1 Plan, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.